JP2008529541A - 腫瘍細胞の分離用容器 - Google Patents
腫瘍細胞の分離用容器 Download PDFInfo
- Publication number
- JP2008529541A JP2008529541A JP2007555539A JP2007555539A JP2008529541A JP 2008529541 A JP2008529541 A JP 2008529541A JP 2007555539 A JP2007555539 A JP 2007555539A JP 2007555539 A JP2007555539 A JP 2007555539A JP 2008529541 A JP2008529541 A JP 2008529541A
- Authority
- JP
- Japan
- Prior art keywords
- container
- tumor cells
- compartment
- biological sample
- separation medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 103
- 238000000926 separation method Methods 0.000 title claims abstract description 75
- 230000009974 thixotropic effect Effects 0.000 claims abstract description 56
- 239000012472 biological sample Substances 0.000 claims abstract description 55
- 239000000126 substance Substances 0.000 claims abstract description 50
- 210000004027 cell Anatomy 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 50
- 230000004888 barrier function Effects 0.000 claims description 44
- 238000005119 centrifugation Methods 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 210000004369 blood Anatomy 0.000 claims description 29
- 239000008280 blood Substances 0.000 claims description 29
- 239000000463 material Substances 0.000 claims description 18
- 239000000523 sample Substances 0.000 claims description 18
- 230000002776 aggregation Effects 0.000 claims description 13
- 238000004220 aggregation Methods 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 12
- 238000010240 RT-PCR analysis Methods 0.000 claims description 11
- 238000003745 diagnosis Methods 0.000 claims description 11
- 210000001124 body fluid Anatomy 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 9
- 238000003752 polymerase chain reaction Methods 0.000 claims description 8
- 229920001971 elastomer Polymers 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 6
- 229920001917 Ficoll Polymers 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 239000000806 elastomer Substances 0.000 claims description 5
- 210000003743 erythrocyte Anatomy 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000975 dye Substances 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 239000005995 Aluminium silicate Substances 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000000389 T-cell leukemia Diseases 0.000 claims description 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 235000012211 aluminium silicate Nutrition 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000000440 bentonite Substances 0.000 claims description 3
- 229910000278 bentonite Inorganic materials 0.000 claims description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 210000000416 exudates and transudate Anatomy 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 claims description 3
- 229910000271 hectorite Inorganic materials 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 238000012760 immunocytochemical staining Methods 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 208000017830 lymphoblastoma Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 230000000405 serological effect Effects 0.000 claims description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000001608 teratocarcinoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 239000011534 wash buffer Substances 0.000 claims description 3
- 239000003130 blood coagulation factor inhibitor Substances 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 150000004760 silicates Chemical class 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 239000002609 medium Substances 0.000 description 51
- 239000000499 gel Substances 0.000 description 13
- 239000010839 body fluid Substances 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 210000004882 non-tumor cell Anatomy 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 229960005423 diatrizoate Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000007898 magnetic cell sorting Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- -1 RNA Chemical class 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000009391 cell specific gene expression Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000018732 detection of tumor cell Effects 0.000 description 1
- 238000011982 device technology Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0093—Purging against cancer cells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5021—Test tubes specially adapted for centrifugation purposes
- B01L3/50215—Test tubes specially adapted for centrifugation purposes using a float to separate phases
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
- B01L2300/044—Connecting closures to device or container pierceable, e.g. films, membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/069—Absorbents; Gels to retain a fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05003640A EP1693109A1 (de) | 2005-02-21 | 2005-02-21 | Behältnis zur Separation von Tumorzellen |
| PCT/EP2006/001496 WO2006087220A2 (de) | 2005-02-21 | 2006-02-20 | Behältnis zur separation von tumorzellen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008529541A true JP2008529541A (ja) | 2008-08-07 |
| JP2008529541A5 JP2008529541A5 (enExample) | 2009-04-09 |
Family
ID=34933847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555539A Pending JP2008529541A (ja) | 2005-02-21 | 2006-02-20 | 腫瘍細胞の分離用容器 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090186341A1 (enExample) |
| EP (1) | EP1693109A1 (enExample) |
| JP (1) | JP2008529541A (enExample) |
| AU (1) | AU2006215776A1 (enExample) |
| CA (1) | CA2642274A1 (enExample) |
| WO (1) | WO2006087220A2 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013168767A1 (ja) | 2012-05-10 | 2013-11-14 | コニカミノルタ株式会社 | 赤血球除去方法および採血用遠沈管 |
| JP2018157812A (ja) * | 2017-03-23 | 2018-10-11 | 東ソー株式会社 | 試料中に含まれる細胞の検出方法 |
| JP2019138838A (ja) * | 2018-02-14 | 2019-08-22 | 住友ゴム工業株式会社 | 特定細胞捕捉方法 |
| US11360078B2 (en) | 2016-09-29 | 2022-06-14 | Sumitomo Rubber Industries, Ltd. | Medical analysis device and cell analysis method |
| US11573232B2 (en) | 2018-02-14 | 2023-02-07 | Sumitomo Rubber Industries, Ltd. | Method for capturing specific cells |
| US11614440B2 (en) | 2019-01-24 | 2023-03-28 | Sumitomo Rubber Industries, Ltd. | Specific cell fractionating and capturing methods |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008022651A1 (en) | 2006-08-21 | 2008-02-28 | Antoine Turzi | Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells |
| EP2067855A1 (de) | 2007-12-07 | 2009-06-10 | Michael W. Dahm | Anreicherung und Nachweis von fetalen Zellen aus maternalem Blut |
| ES2390171T3 (es) | 2008-07-21 | 2012-11-07 | Becton, Dickinson And Company | Dispositivo de separación de fases de densidad |
| JP5607621B2 (ja) | 2008-07-21 | 2014-10-15 | ベクトン・ディキンソン・アンド・カンパニー | 密度相分離デバイス |
| CN104588140B (zh) | 2008-07-21 | 2016-06-29 | 贝克顿·迪金森公司 | 密度相分离装置 |
| EP2918344B1 (en) | 2009-05-15 | 2021-06-30 | Becton, Dickinson and Company | Density phase separation device |
| WO2011069145A2 (en) * | 2009-12-04 | 2011-06-09 | Becton, Dickinson And Company | Blood collection tube with separation barrier |
| EP2500095A1 (de) * | 2011-03-15 | 2012-09-19 | Siemens Healthcare Diagnostics Products GmbH | Vorrichtungen und Verfahren zur Bestimmung der Plättchenfunktion in einem Zentrifugalanalyzer |
| EP2810717B1 (en) * | 2013-06-06 | 2018-10-17 | F. Hoffmann-La Roche AG | Acceleration sensitive indicator |
| WO2014202957A1 (en) | 2013-06-19 | 2014-12-24 | Brightwake Limited | Cell collecting device |
| US9694359B2 (en) | 2014-11-13 | 2017-07-04 | Becton, Dickinson And Company | Mechanical separator for a biological fluid |
| CN105368706A (zh) * | 2015-12-11 | 2016-03-02 | 何守贵 | 大容量单个核细胞分离瓶 |
| US20210146352A1 (en) * | 2017-07-24 | 2021-05-20 | Epitope Diagnostics, Inc. | Fecal sample collection and analyte extraction device and method |
| KR20240005874A (ko) * | 2021-05-05 | 2024-01-12 | 살루스 디스커버리 엘엘씨 | 안정적인 계면 시스템 및 조성물 |
| CN114832471A (zh) * | 2022-05-20 | 2022-08-02 | 深圳华大医学检验实验室 | 一种滤芯及其过滤装置与方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0720122A (ja) * | 1992-06-11 | 1995-01-24 | Becton Dickinson & Co | 凝固阻止溶液およびそれを用いた分離器具と分離法 |
| JP2002536635A (ja) * | 1999-02-03 | 2002-10-29 | ダーム、ミヒャエル・ヴェー | 体液から腫瘍細胞を濃縮するか又は除去する方法及びかかる目的に適したキット |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4844818A (en) * | 1987-10-23 | 1989-07-04 | Becton Dickinson & Company | Method for separating the cellular components of blood samples |
| US4867887A (en) * | 1988-07-12 | 1989-09-19 | Becton Dickinson And Company | Method and apparatus for separating mononuclear cells from blood |
| US5840502A (en) * | 1994-08-31 | 1998-11-24 | Activated Cell Therapy, Inc. | Methods for enriching specific cell-types by density gradient centrifugation |
| CA2239729C (en) * | 1995-12-11 | 2006-10-31 | Dendreon Corporation | Cell separation composition, kit and method |
| DE50309796D1 (de) * | 2002-08-14 | 2008-06-19 | Hexal Gentech Forschungsgmbh | Verfahren zum immunzytologischen oder molekularen nachweis von disseminierten tumorzellen aus einer körperflüssigkeit und dazu geeigneter kit |
-
2005
- 2005-02-21 EP EP05003640A patent/EP1693109A1/de not_active Withdrawn
-
2006
- 2006-02-20 US US11/816,742 patent/US20090186341A1/en not_active Abandoned
- 2006-02-20 JP JP2007555539A patent/JP2008529541A/ja active Pending
- 2006-02-20 CA CA002642274A patent/CA2642274A1/en not_active Abandoned
- 2006-02-20 WO PCT/EP2006/001496 patent/WO2006087220A2/de not_active Ceased
- 2006-02-20 AU AU2006215776A patent/AU2006215776A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0720122A (ja) * | 1992-06-11 | 1995-01-24 | Becton Dickinson & Co | 凝固阻止溶液およびそれを用いた分離器具と分離法 |
| JP2002536635A (ja) * | 1999-02-03 | 2002-10-29 | ダーム、ミヒャエル・ヴェー | 体液から腫瘍細胞を濃縮するか又は除去する方法及びかかる目的に適したキット |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013168767A1 (ja) | 2012-05-10 | 2013-11-14 | コニカミノルタ株式会社 | 赤血球除去方法および採血用遠沈管 |
| US11360078B2 (en) | 2016-09-29 | 2022-06-14 | Sumitomo Rubber Industries, Ltd. | Medical analysis device and cell analysis method |
| JP2018157812A (ja) * | 2017-03-23 | 2018-10-11 | 東ソー株式会社 | 試料中に含まれる細胞の検出方法 |
| JP2019138838A (ja) * | 2018-02-14 | 2019-08-22 | 住友ゴム工業株式会社 | 特定細胞捕捉方法 |
| JP7170254B2 (ja) | 2018-02-14 | 2022-11-14 | 住友ゴム工業株式会社 | 特定細胞捕捉方法 |
| US11573232B2 (en) | 2018-02-14 | 2023-02-07 | Sumitomo Rubber Industries, Ltd. | Method for capturing specific cells |
| US11614440B2 (en) | 2019-01-24 | 2023-03-28 | Sumitomo Rubber Industries, Ltd. | Specific cell fractionating and capturing methods |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090186341A1 (en) | 2009-07-23 |
| CA2642274A1 (en) | 2006-08-24 |
| WO2006087220A2 (de) | 2006-08-24 |
| AU2006215776A1 (en) | 2006-08-24 |
| EP1693109A1 (de) | 2006-08-23 |
| WO2006087220A3 (de) | 2006-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008529541A (ja) | 腫瘍細胞の分離用容器 | |
| DK2542689T3 (en) | Method for isolating target cells | |
| Warkiani et al. | An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells | |
| CA2338751C (en) | Cancer cells from body fluids containing cells, isolation thereof and agents containing the same | |
| AU768538B2 (en) | Method for enriching or depleting tumour cells obtained from a body fluid and kit suitable for this purpose | |
| WO2006050352A1 (en) | Blood test prototypes and methods for the detetion of circulating tumor and endothelial cells | |
| CN107075556B (zh) | 使用基于磁性和尺寸的分离进行细胞分离的方法和系统 | |
| WO2005043121A2 (en) | Blood test prototypes and methods for the detection of circulating tumor and endothelial cells | |
| Au et al. | Clusters of circulating tumor cells: a biophysical and technological perspective | |
| Almeida et al. | Cell purification: a new challenge for biobanks | |
| KR20160019475A (ko) | 체액으로부터의 산발성 세포를 분리하는 방법 및 상기 방법을 수행하기 위한 장치 | |
| JP2008529541A5 (enExample) | ||
| Costa et al. | Methodology for the isolation and analysis of CTCs | |
| WO2014127314A1 (en) | Devices and methods for purification of biological cells | |
| JP6617516B2 (ja) | 血液試料中に含まれる目的細胞の検出方法 | |
| US20130052647A1 (en) | Methods for fractionating and processing microparticles from biological samples and using them for biomarker discovery | |
| US20180030507A1 (en) | Method and apparatus relating to treatment of a blood sample for sequencing of circulating tumour cells | |
| CN111751543A (zh) | 一种稀有肿瘤细胞富集方法及试剂盒 | |
| JP6173577B1 (ja) | 細胞増殖法を用いた循環腫瘍細胞の検出・分離取得方法 | |
| Teixeira et al. | Advances in Microfluidics for the Implementation of Liquid Biopsy in Clinical Routine | |
| CN114096849A (zh) | 使用了病毒的循环肿瘤细胞的检测方法 | |
| JP2018157812A (ja) | 試料中に含まれる細胞の検出方法 | |
| Guglielmi | Investigations to improve CTC-based liquid biopsy in pancreatic ductal adenocarcinoma by screening high volume of blood | |
| JP7279542B2 (ja) | 試料中に含まれる目的細胞の定量方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090218 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090218 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20100706 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100706 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111004 |